Axogen Stock Drops After $209 Million Share Sale to Fund NerveTape Deal

Axogen will use proceeds from a $208.7 million stock offering to buy BioCircuit Technologies and its NerveTape device, the first FDA-cleared sutureless option for peripheral nerve repair.